Martin Lauss, Bengt Phung, Troels Holz Borch, Katja Harbst, Kamila Kaminska, Anna Ebbesson, Ingrid Hedenfalk, Joan Yuan, Kari Nielsen, Christian Ingvar, Ana Carneiro, Karolin Isaksson, Kristian Pietras, Inge Marie Svane, Marco Donia, Göran Jönsson
Immune checkpoint blockade (ICB) has improved outcome for patients with metastatic melanoma but not all benefit from treatment. Several immune- and tumor intrinsic features are associated with clinical response at baseline. However, we need to further understand the molecular changes occurring during development of ICB resistance. Here, we collect biopsies from a cohort of 44 patients with melanoma after progression on anti-CTLA4 or anti-PD1 monotherapy. Genetic alterations of antigen presentation and interferon gamma signaling pathways are observed in approximately 25% of ICB resistant cases...
April 9, 2024: Nature Communications